PARKASH S. GILL, M.D.; MARK RARICK, M.D.; RUSSELL K. BRYNES, M.D.; DENNIS CAUSEY, M.D.; CARMEN LOUREIRO, M.D.; ALEXANDRA M. LEVINE, M.D.
Four patients with the acquired immunodeficiency syndrome, and a history of Pneumocystis carinii pneumonia developed severe pancytopenia (hemoglobin, < 85 g/L; granulocytes, ≤ 0.5 x 109/L; platelets, ≤ 30 x 109/L) 12 to 17 weeks after the initiation of azidothymidine (AZT) therapy. The bone marrow was markedly hypocellular in three patients and moderately hypocellular in the fourth. Partial bone marrow recovery was documented within 4 to 5 weeks in three patients, but no marrow recovery has yet occurred in one patient during the more than 6 months since AZT treatment was discontinued. Azidothymidine should be used cautiously, with close monitoring of blood values.
GILL PS, RARICK M, BRYNES RK, CAUSEY D, LOUREIRO C, LEVINE AM. Azidothymidine Associated with Bone Marrow Failure in the Acquired Immunodeficiency Syndrome (AIDS). Ann Intern Med. ;107:502–505. doi: 10.7326/0003-4819-107-4-502
Download citation file:
Published: Ann Intern Med. 1987;107(4):502-505.
Hematology/Oncology, Infectious Disease.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use